Teleflex Announces European Market Clearance for its Innovative Vascular Access Catheter

<0> Teleflex IncorporatedJake ElguiczeTreasurer and Vice President, Investor Relations610-948-2836 </0>

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery, has announced that its Semprus BioSciences subsidiary has been issued CE certification from its notified body, the DEKRA Certification Group of The Netherlands, to market the company's Nylus™ Peripherally Inserted Central Catheter (PICC) with Semprus Sustain™ technology to the European Union.

The Nylus PICC uses a long-lasting polymer designed to reduce the attachment of platelets and blood proteins at the surface of the medical device. This provides benefits to the patient, the caregiver and the health care system. The Nylus PICC has been shown to reduce platelet adhesion and thrombus accumulation through and animal testing.

"This clearance enables us to further advance a new standard of care in PICC catheters,” commented David L. Lucchino, Vice President of Semprus Technology, Strategic and Business Development of Teleflex. “Our novel technology, with its ability to work in blood products and long-term duration, holds great potential to reduce infection and thrombus-related complications for patients – while substantially decreasing associated healthcare costs.”

Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. Our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. Headquartered in Limerick, PA, Teleflex employs approximately 11,200 people worldwide and serves healthcare providers in more than 130 countries. Additional information about Teleflex can be obtained from the company's website at .

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Suggested Articles

A new, late-phase analysis of cholesterol-lowering inclisiran showed that it was able to cut LDL levels by 51% after nearly a year and a half.

The data were highly anticipated, especially since the two partners continued testing after the compound missed its endpoints in phase 2 studies.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.